Saad S. Kenderian

Aug 11, 2024 | nature.com | Razan Mohty |Radhika Bansal |Urshila Durani |Madiha Iqbal |Yucai Wang |Jonas Paludo | +8 more

Dear Editor,Hemophagocytic lymphohistiocytosis (HLH) is a rare complication of chimeric antigen receptor T-cell (CAR-T) therapy [1,2,3]. With the increasing use of CAR-T therapy in treating hematological malignancies, the unique phenomenon of CAR-T-associated HLH (carHLH) is increasingly recognized. Albeit rare, reported rates vary from 1–3% to 35% depending on the underlying disease, patient population and the CAR-T product [1,2,3].

Aug 25, 2023 | nature.com | Saad S. Kenderian

AbstractChimeric antigen receptor T (CAR-T) cell therapy has drawn increasing attention over the last few decades given its remarkable effectiveness and breakthroughs in treating B cell hematological malignancies. Even though CAR-T cell therapy has outstanding clinical successes, most treated patients still relapse after infusion.

Jun 6, 2023 | thelancet.com | Tanya Siddiqi |David Maloney |Saad S. Kenderian

Background Patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma for whom treatment has failed with both Bruton tyrosine kinase (BTK) inhibitor and venetoclax have few treatment options and poor outcomes. We aimed to evaluate the efficacy and safety of lisocabtagene maraleucel (liso-cel) at the recommended phase 2 dose in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma.